The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19.
Lancet Healthy Longev
; 2(2): e105-e111, 2021 02.
Article
en En
| MEDLINE
| ID: mdl-33665645
COVID-19 disproportionately affects older people, with likelihood of severe complications and death mirroring that of other age-associated diseases. Inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) has been shown to delay or reverse many age-related phenotypes, including declining immune function. Rapamycin (sirolimus) and rapamycin derivatives are US Food and Drug Administration-approved inhibitors of mTORC1 with broad clinical utility and well established dosing and safety profiles. Based on preclinical and clinical evidence, a strong case can be made for immediate large-scale clinical trials to assess whether rapamycin and other mTORC1 inhibitors can prevent COVID-19 infection in these populations and also to determine whether these drugs can improve outcomes in patients with severe COVID-19.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
COVID-19
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Lancet Healthy Longev
Año:
2021
Tipo del documento:
Article
País de afiliación:
China